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Summary NCRC-11 is an IgM monoclonal antibody which defines an antigen found in most epithelial
malignancies. The antigen has previously been shown to be a high mol. wt. glycoprotein (>400,000) and in
this study, antigen preparations were isolated by immunoadsorbent chromatography from ovarian mucinous
and ovarian serous cyst adenocarcinoma and from breast carcinoma. Other monoclonal antibodies, against
products in normal human milk, and antibodies of the Ca series (Bramwell et al., 1985) reacted with all three
antigen preparations. Tests involving epitope mapping were performed to probe the relationships of the
various epitopes to that defined by the NCRC-11 antibody, and, of note, the three antigen preparations from
different tumour sources were remarkably similar with respect to their relative levels of epitope expression and
to their topographical distribution of epitopes. The major differences in epitope expression could be attributed
to the degree of sialylation in the three antigens. The antigens from ovarian tumours expressed I(Ma) blood
group determinants (defined by the antibody LICR-LON-M18) which were partially masked by sialic acid.
With NCRC- 11 defined antigen from breast carcinoma, this determinant was totally masked by sialic acid
although neuraminidase treatment clearly exposed epitopes reactive with M18 antibodies.
NCRC-l1 is a murine monoclonal antibody which
was originally prepared against dissociated human
primary breast carcinoma cells (Ellis et al., 1984).
Immunocytochemical studies have shown that the
antigen has a wide but highly specific distribution
in normal tissue, being virtually confined to the
surface of certain epithelial cell types. With breast
carcinomas, tumours were stained in a variable
manner, the intensity of the reaction being directly
related to patient survival (Ellis et al., 1985). These
findings have prompted investigations upon
characterizing the target antigen defined by the
NCRC-11 antibody and the results indicate that it
is a large glycoprotein of apparent molecular
weight of greater than 400,000 (Price et al., 1985).
This antigen, isolated by immunoadsorbent
chromatography of detergent extracts of breast
carcinoma subcellular membranes, displays an
affinity for the lectin, wheat germ agglutinin, and is
sensitive to pronase and papain, although antibody
binding is unaffected by heat (100°C for 5min) or
neuraminidase. The antigen thus appears similar to
antigens such as the MAM-6 antigen (Hilkens et
al., 1984; 1985) the epithelial membrane antigen,
EMA (Ormerod et al., 1985) and PAS-O (Shimizu
and Yamauchi, 1982), each of which have been
purified from human milk. Comparably, the
NCRC-l1 defined antigen also resembles the Cal
antigen from normal urine (Bramwell et al., 1983).
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It is likely that the NCRC- 1I antigen, isolated from
breast carcinomas belongs to a family of similar
high molecular weight glycoproteins which are
confined to specialized epithelia.
In the present study, NCRC-l1-defined antigens
have been purified for further analysis from three
different tumour sources: these include ovarian
mucinous adenocarcinoma, ovarian serous cyst
adenocarcinoma and breast carcinoma. These three
antigen preparations isolated by immunoadsorbent
chromatography using immobilized NCRC-l1
antibodies, have been compared in sensitive epitope
mapping tests using a panel of well-characterized
monoclonal antibodies several of which have
previously been shown to be reproducibly reactive
with NCRC-11 antigen preparations from breast
carcinomas (Price et al., 1985). The findings
obtained have relevance with regard to developing
diagnostic and prognostic assays for gynaecological
tumours using antibodies which react with
oligosaccharide epitopes on a widely expressed
differentiation antigen or family of closely related
antigenic molecules.
Materials and methods
Monoclonal antibodies
The monoclonal antibody, NCRC-11 (IgM) was
originally prepared using spleen cells from a Balb/c
mouse immunized against dissociated breast
carcinoma cells (Ellis et al., 1984). The following
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anti-human milk fat globule membrane antibodies
were also employed: HMFG-1 (IgGI) and HMFG-
2 (IgGl) (Taylor-Papadimitriou et al., 1981); an
anti-human epithelial membrane antigen mono-
clonal antibody termed EMA (IgG2a) also known
as E29 (Heyderman et al., 1985) from Dakopatts
a/s (High Wycombe, Bucks.); LICR-LON-M8
(IgGl), LICR-LON-M18 (IgM) and LICR-LON-
M24 (IgM) abbreviated to M8, M18 and M24
respectively (Edwards & Brooks, 1984); 115D8,
115F5 (IgGI) and 115G2 (IgG2) (Hilkens et al.,
1984). The antibody Cal (IgM) was prepared
against wheat germ agglutinin-binding glyco-
proteins from cultured human laryngeal carcinoma
H.Ep2 cells (Ashall et al., 1982). Ca2 (IgGI) and
Ca3 (IgG1) were both prepared by immunization
with the purified Cal-defined antigen (Bramwell et
al., 1985).
The antibody 11.285.14 (IgG1) is specific for
carcinoembryonic antigen (CEA) (Corvalan et al.,
1984). The antibodies C154 and C161 were both
prepared by immunization with human colon
carcinoma subcellular membranes, and C161 is
reactive with the normal cross-reacting antigen,
NCA-1, while C154 reacts with a wide range of
normal and tumour tissues (L. Durrant -
unpublished findings). Monoclonal antibodies
791T/36 and 791T/48 (both IgG2b) were prepared
against human osteogenic sarcoma cells (Embleton
et al., 1981). The anti-HLA-A,B,C (shared deter-
minant) Clone W6/32 monoclonal antibody was
obtained from Sera-Lab (Crawley Down, Sussex)
and normal mouse IgM was from Miles Laboratories
(Stoke Poges, Slough).
NCRC-l 1 antibody was purified from ascitic
fluids by its binding to, and elution from, a
Sepharose-lentil lectin affinity column (Pharmacia,
Uppsala, Sweden), its protein concentration being
determined assuming E'Ok,onm= 11.9.
Purification ofNCRC-JJ defined antigens
Tumour tissue from specimens of ovarian mucinous
adenocarcinoma, ovarian serous cyst adeno-
carcinoma and breast carcinoma was homogenized
in phosphate buffered saline, pH 7.3 (PBS)
containing 5mMMgCl2, at 4mlg 1 tissue, and an
extra-nuclear membrane (ENM) preparation was
isolated as the 105,000g pellets of 600g super-
natants of the homogenate (Price & Baldwin, 1974).
NCRC-l 1 antibody reactivity with these ENM
preparations was confirmed firstly using an ENM-
antibody binding assay (Price et al., 1986) and
secondly by demonstrating that NCRC-1 1 antibody
bound to high molecular weight antigens
(>400,000 - as reported previously - Price et al.,
1985) transferred by electroblotting to nitrocellulose
paper from sodium dodecyl sulphate poly-
acrylamide gels (Towbin et al., 1979) and stained
with peroxidase-linked rabbit anti-mouse Ig and
diaminobenzidine.
Detergent (Nonidet P-40) soluble extracts were
prepared from ENM pellets, and the extracts were
fractionated by immunoadsorbent chromatography
using Sepharose-linked NCRC-l1 antibody as
previously reported (Price et al., 1985). The
procedure is based upon that described by
Blaszczyk et al. (1984) and it incorporates extensive
washing of the immunoadsorbent with buffers
containing detergent and high salt to eliminate non-
specifically bound material, before antigen is eluted
with 100mm diethylamine, pH 11.5. Fractions
retaining NCRC-11 antibody binding activity were
identified using a microradioisotopic antiglobulin
assay and pooled fractions with antigenic activity
were dialysed against PBS before storage in small
aliquots at -20°C.
NCRC-JJ antigen binding assay
NCRC-11 defined antigen preparations (diluted
1/10 in PBS), were added to microtest plates
(Falcon 3034F microtest Terasaki tissue culture
plates, Becton Dickinson, Oxnard CA) at 10p1/well
and air dried at 370C for 3 to 4h. It was not
possible to detect and quantitate protein
concentration in the final NCRC-11 antigen
preparations by the method of Lowry et al. (1951)
although in antigen titration tests a dilution of 1/10
in PBS was determined to be satisfactory for
coating the wells of microtest plates. The wells were
washed 4 times with a washing buffer consisting of
PBS+0.1% bovine serum albumin (BSA)+0.1%
rabbit serum (RbS)+0.02% NaN3. During the
final wash cycle, the wells were incubated for
30min with washing buffer to complete the
blocking of non-specific adsorption sites.
Monoclonal antibodies diluted in washing buffer,
or washing buffer alone in negative controls, were
added at 10p1/well in replicates of 5 or 6. All
monoclonal antibodies were added at concen-
trations or dilutions predetermined to be at
saturation (i.e. neat hybridoma tissue culture super-
natants, ascitic fluids at a dilution of 1/1000 or
purified antibodies at 5pgml-1. After incubation
for 1 to 2h at room temperature, the wells were
aspirated and washed 4 times. 1251-labelled affinity
purified F(ab')2 fragments of rabbit anti-mouse Ig
were added at approximately 105 c.p.m./10l/well
(radioiodination of this reagent was performed
using the chloramine T procedure of Jensenius &
Williams (1974) using 500,pCi 1251 per 25pg
protein). Incubation was continued for 1 to 2h at
room temperature. The wells were aspirated, then
washed 6 times, after which the radioactivity in
each well was determined.EPITOPES OF OVARIAN AND BREAST CARCINOMA ANTIGENS
The non-specific binding of antibodies to 'PBS-
coated' and 'BSA/RbS-blocked' wells was deter-
mined and the values obtained were subtracted
from those determined with antigen-coated, BSA/
RbS-blocked and antibody-treated wells. In this
assay, reproducibly positive antibody binding
reactions are represented by the retention of more
than 500c.p.m./well (Price et al., 1986).
Competitive inhibition of 125I-NCRC-JJ antibody
binding
NCRC-11 monoclonal antibody was labelled with
125I to give a specific activity of approximately
30uCi/pg (Fraker & Speck, 1978). Labelled
antibody (2 x 107c.p.m. ml-1 - corresponding to
-0.6ugml-1) was admixed with equal volumes
of hybridoma supernatant or ascitic fluids (diluted
in w2-hing buffer), or washing buffer alone. The
ranges )f dilution tested (from neat to 1/103 for
supernatants and from 1/103 to 1/106 for ascitic
fluids) were selected since they were predetermined
to ensure saturation of antigen at least at the
highest concentration tested. The mixtures were
dispensed into NCRC-11 antigen coated wells with
the 1251-NCRC-11 antibody added at 105 c.p.m./
10gl/well (i.e. 3 ng NCRC-11 antibody/1 td/well).
After incubation for 1 to 2h at room temperature,
the wells were aspirated, then washed 6 times, after
which time the radioactivity in each well was
determined.
Sandwich assay
Hybridoma ascitic fluids (1/500 in PBS+0.02%
NaN3) were adsorbed on to the wells of microtest
plates at 10 IO/well. After incubation at 5°C for
18h, the wells were aspirated and washed 4 times
with washing buffer. Aliquots (10p1) of NCRC-11
antigen or washing buffer alone were added to the
wells. After incubation for 1 h at room temperature,
the wells were aspirated and washed 4 times.
125I-NCRC-1 1 antibody was dispensed at
105c.p.m./10Ml/well and incubated for 1 h at room
temperature. The wells were aspirated, then washed
6 times, after which the radioactivity in each well
was determined.
Results
Epitope expression in NCRC-JJ antigen preparations
from ovarian and breast carcinomas
Table I shows the results of testing a panel of
monoclonal antibodies against immunoadsorbent-
purified, NCRC-11 antibody defined antigen
preparations, isolated from two ovarian tumours -
a mucinous adenocarcinoma and a serous cyst
Table I Reactivity of monoclonal antibodies with
NCRC-1 1-defined antigen preparations isolated from
ovarian and breast tumours
Mean c.p.m. +s.d. (-background) bound to
NCRC-J1 defined antigen isolatedfrom:
Ovarian- Ovarian-
mucinous serous cyst
adeno- adeno- Breast
Antibody carcinoma carcinoma carcinoma
NCRC-11 7,274+116 2,920+80 7,430+ 152
HMFG-1 9,380+257 2,935+215 5,333+219
HMFG-2 7,485+449 3,397+82 6,408+ 151
EMA 7,786+214 3,170+ 128 7,477+383
M8 7,176+241 3,720+119 7,042+ 180
M18 1,980+235 655+61 18+66
M24 117+61 100+52 154+ 148
115D8 13,238+305 5,659+236 13,931 +254
115F5 6,343+467 3,716+ 155 5,989+ 158
115G2 2,843+105 921+23 318+171
Cal 3,867+232 317+74 4,837+ 186
Ca2 6,954+206 2,483+61 5,667+ 139
Ca3 5,946+38 2,095+116 6,743+73
adenocarcinoma - and from breast carcinoma. The
binding of antibodies to antigen preparations
adsorbed to the wells of Terasaki microtest plates
was assessed using a microradioisotopic
antiglobulin assay. Ten of the antibodies reacted
strongly with the NCRC- 1I antigen from breast
carcinoma, while M18, M24 and 115G2 failed to
react with this antigen. The profiles of reactivity of
the 13 antibodies with NCRC-11-defined antigens
from the ovarian mucinous and serous cyst adeno-
carcinomas were very similar to that obtained with
the breast carcinoma antigen, although overall,
antibody reactivity with the ovarian serous cyst
adenocarcinoma antigen was lower than with the
other two antigen preparations. Both ovarian
carcinoma antigens expressed epitopes for the anti-
human milk fat globule membrane antibodies M18
and 115G2 which were not apparently expressed in
the breast carcinoma antigen preparation (Table I).
The only other major difference in epitope
expression in these three antigen preparations was
that the reaction of Cal with the ovarian serous
cyst adenocarcinoma antigen was much reduced in
comparison with its reactivity with the other
antigens.
Table II shows the results of further tests
examining the reactivity of monoclonal antibodies
with the three antigen preparations. No antigen
binding was obtained with antibodies reactive
against colonic tumours including C154 which
binds to a variety of normal and tumour tissues
and antibodies C161 and 11.285.14 which react
395396 M.R. PRICE et al.
Table II Reactivity of monoclonal antibodies with
NCRC-11-defined antigen preparations isolated from
ovarian and breast tumours
Mean c.p.m. +s.d.(-background) bound to
NCRC-JJ defined antigen isolatedfrom:
Ovarian- Ovarian-
mucinous serous cyst
adeno- adeno- Breast
Antibody carcinoma carcinoma carcinoma
NCRC-l1 6,376+91 2,685+51 7,343 +318
C154 -7+55 -130+44 61 +43
C161 -15+61 22+20 39+109
11.285.14 78+36 -17+84 -42+86
791T/36 -105+17 -10+43 18+30
791T/48 71+23 59+ 15 -41+98
W6/32 391 +259 173+241 140+238
IgM 39+35 58+ 55 -53+75
NMS -104+52 162+37 148+66
with NCA-1 and CEA, respectively. Antibodies
against human osteogenic sarcomas (79IT/36 and
791T/48) and against HLA-A,B,C (shared
determinant) (W6/32), as well as normal mouse
IgM and normal mouse serum, failed to bind to
any of the antigen preparations.
Competitive inhibition of125I-NCRC-11 antibody
binding
The monoclonal antibodies listed in Table I were
assayed for their capacity to inhibit the binding of
1251-NCRC-11 antibody to the three NCRC-11
antigen preparations adsorbed to the wells of the
microtest plates. Both tissue culture supernatants
and ascitic fluids were used as the source of
antibody. With each individual antibody, and at
any antibody dilution tested, its capacity to inhibit
the binding of 125I-NCRC-11 antibody to thc 3
antigens was virtually identical (Figures 1 aind 2').
On the basis of these tests, the antibodies could be
divided into several categories with respect to their
capacity to inhibit 125I-NCRC-11 antibody binding
to each of the three antigen preparations.
Antibodies EMA and M8 were potent inhibitors of
125I-NCRC-11 antibody binding and they were
similar in their inhibitory activity to unlabelled
NCRC-11 antibody (Figure 1, panels a and d;
Figure 2, panels a and b). Antibodies HMFG-1 and
HMFG-2, and to a lesser extent antibodies Cal,
Ca2 and Ca3 partially inhibited 125I-NCRC-1 1
antibody binding to the ovarian and breast
carcinoma antigens (Figure 1, panels b, c, e, f and g
respectively). Essentially, non-inhibitory antibodies
include 115D8 and 11SF5 (Figure 2, panels e and f)
which react strongly with all three NCRC-11
antigen preparations (Table I) as well as antibodies
M18, M24 and 115G2 (Figure 2, panel c, d and
g respectively) which react weakly or not at all
with the ovarian and breast carcinoma antigens
(Table I).
Sandwich immunoassay
A sandwich immunoassay was employed to confirm
the co-expression of monoclonal antibody defined
epitopes on the same molecules in each of the three
NCRC-l 1 antigen preparations from ovarian and
breast carcinomas. These tests were performed with
those antibodies which were strongly reactive with
the antigen preparations and which were available
as ascitic fluids (using hybridoma supernatants,
insufficient antibody is adsorbed to the wells to
capture added NCRC-l 1 antigen detectable with
radiolabelled NCRC-l 1 antibody).
As shown in Table III, 1251I-labelled NCRC-l 1
antibody bound to wells coated with NCRC-11,
115D8, 115F5 and M8 antibodies and to which the
three antigens had been added. No binding was
obtained with wells treated with buffer rather than
antigen. Thus, in order for 1251I-labelled NCRC-1 1
antibody to bind to antigen bound to the adsorbed
NCRC-l1 antibodies (as was the case with each
antigen), NCRC-11 epitopes must represent
repeated structures on the antigens. Also, for
binding of 125I-labelled NCRC-11 antibody to
antigen treated wells which were coated with
115D8, 11SF5 or M8 antibodies, then the epitopes
Table III Analysis of epitope expression on NCRC-11
defined antigen preparations using a sandwich
immunoassay
Binding of 125I-NCRC-1J antibody to
antibody-coated wells treated with NCRC-1J
antigen isolatedfrom:
Wells
coatedwith Ovarian- Ovarian-
ascitic mucinous serous cyst
fluid adeno- adeno- Breast
(1/500) carcinoma carcinoma carcinoma
NCRC-l1 6,687+94 3,362+105 7,425+464
(_93+43)a (80+23) (76+46)
llSD8 7,762+ 179 3,155+47 8,617+489
(-31+8) (135+13) (163+23)
115F5 1,382 ±271 1,065+246 1,789+128
(-86+35) (120+73) (147+10)
M8 1,781 +243 719+43 1,859+86
(-86+24) (94+13) (129+13)
aFigures in parenthesis represent the binding of 1251-
NCRC-1 1 antibody in the absence ofantigen.EPITOPES OF OVARIAN AND BREAST CARCINOMA ANTIGENS
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Figure 1 Competitive inhibition of binding of 125I-NCRC-1 1 antibody to NCRC-11 defined antigens
isolated from ovarian mucinous carcinoma ( 0), ovarian serous cyst carcinoma (R ), and breast
carcinoma (A A). Monoclonal antibodies in hybridoma tissue culture supernatants were examined for
their capacity to inhibit 125I-labelled antibody binding at the dilutions shown.
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Figure 2 Competitive inhibition of binding of '25I-NCRC-l 1 antibody to NCRC-11 deflned antigens
isolated from ovarian mucinous carcinoma ( 0), ovarian serous cyst carcinoma (R *), and breast
carcinoma (A A). Monoclonal antibodies in ascitic fluids (panels a to g) and normal mouse serum (NMS
- panel h) were examined for their capacity to inhibit 125I-NCRC-1 1 antibody binding at the dilutions shown.
aNCRC-11 b HMFG-1 c HMFG-2 d EMA
e Cal f Ca2 g Ca3
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defined by 115D8, 115F5 and M8 antibodies must
be co-expressed with NCRC-11 defined epitopes
upon at least a proportion of the NCRC-11
antigenic molecules isolated from the three tumour
sources.
Neuraminidase treatment ofNCRC-JJ antigens
Desialylation of breast tumour tissue sections with
neuraminidase reveals the immunodominant oligo-
saccharide sequence of the I(Ma) blood group
antigen, Galfl,-B4GlcNAc,Bl1-6-, defined by the
monoclonal antibody M18 (Foster & Neville, 1984).
The three NCRC-11 defined antigen preparations
were treated with neuraminidase and then examined
for their capacity to bind the M18 antibody.
Untreated and treated antigen preparations were
also examined for their capacity to bind the
antibodies NCRC-11 and Cal. Measurement of the
effect of neuraminidase on Cal binding was
included as a positive control for the enzyme
digestion, since the epitope for Cal involves sialic
acid (Bramwell et al., 1985). As shown in Figure 3,
neuraminidase treatment of NCRC-11 antigens
from ovarian and breast carcinomas did not modify
their capacity to bind NCRC-11 antibody, whereas
the binding of Cal to the treated antigens was
virtually abolished. Conversely, the binding of the
M18 antibody was considerably increased with the
neuraminidase treated antigens. This is most clearly
shown with NCRC-11 antigen from breast
carcinoma - the M18 antibody failed to bind to the
untreated antigen (Table I and Figure 3c) whereas
its binding to neuraminidase treated antigen was
64% of the level of NCRC-l1 antibody binding
(Figure 3c).
Discussion
The three antigen preparations described in this
report were isolated from the two major types of
malignant ovarian carcinoma (mucinous. and
serous) and from breast carcinoma. The antigen
preparations were purified by their binding to, and
elution from, Sepharose-linked NCRC-11 anti-
bodies, so that all molecules in each antigen
preparation should express the NCRC-11 epitopes.
By normalizing the data in Table I, so that the
reactivity of NCRC-11 antibody with each antigen
is equalized, a profile of antibody reactivity with
the three antigens may be constructed. As shown in
Figure 4 this type of epitope profile illustrates the
remarkable similarity in the three antigen
preparations with respect to their reactivity with the
antibodies tested. Of note, the antibody Cal
displayed the most variability in expression between
the three antigen preparations. This may be due to
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Figure 3 NCRC-11, Cal and M18 binding to
neuraminidase treated NCRC-11 antigen preparations
isolated from (a) ovarian mucinous carcinoma, (b)
ovarian serous cyst carcinoma, and (c) breast
carcinoma. Antigen preparations were adsorbed to the
wells of microtest plates and treated for 60min at
37°C with control buffer solutions or neuraminidase
(Clostridium perfringens Type V neuraminidase at
lOOmUml-' in 200mM sodium acetate buffer,
pH 5.5 containing 1 mm phenyl methyl sulphonyl
fluoride, PMSF). Open bars represent antibody
binding after treatment with washing buffer, hatched
bars represent antibody binding after treatment with
sodium acetate/PMSF buffer and solid bars show
antibody binding after neuraminidase treatment. After
buffer or enzyme treatment, the plates were washed 4
times and blocked with washing buffer for 1 h before
the addition of antibodies. Error bars represent s.d.
variability in the degree of sialylation of the three
antigens since the Cal epitope involves sialic acid
(Bramwell et al., 1985). Neuraminidase treatment of
antigens abolished Cal binding activity but clearly
resulted in an increase in the binding of the M18
antibody (Figure 3). In this case, the excess
sialylation of the I(Ma) blood group antigen,
defined by the M18 antibody, leaves this
determinant in a cryptic or masked form.EPITOPES OF OVARIAN AND BREAST CARCINOMA ANTIGENS 399
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Figure 4 Profile of monoclonal antibody binding to
NCRC-11-defined antigens from ovarian mucinous
carcinoma, ovarian serous cyst carcinoma and breast
carcinoma.
Tests examining the capacity of various
antibodies to inhibit the binding of 1251I-NCRC-1
antibody to the three antigen preparations were
performed. With any one of the antibodies tested
the inhibition curves with the three antigens were
co-incidental (Figures 1 and 2). This infers that the
topographical disposition of epitopes defined by
any one of the antibodies tested, in relation to
epitopes defined by the NCRC-11 antibody, is the
same or remarkably similar in each of the three
antigen preparations. The degree of inhibition of
binding of 125I-NCRC-11 antibody to antigen
(Figures 1 and 2) was not related to the magnitude
of the reaction of that antibody with the antigen.
Thus, the 115D8 antibody, which reacts strongly
with each antigen (Table I; Figure 4) failed to
inhibit or modify t251-NCRC-11 antibody binding
(Figure 2). Sandwich immunoassays confirmed that
NCRC-11 and 115D8 epitopes are indeed co-
expressed on the same molecules (Table III).
The NCRC-11 defined antigens as isolated from
ovarian and breast tumours, clearly express a
number of important epitopes defined by several
well characterized monoclonal antibodies. It is of
interest that antibody binding reactions to these
various epitopes have been exploited for diverse
purposes in relation to breast cancer and malignant
ovarian tumours. Taking a number of examples,
NCRC-11 antibody binding to tissue sections is of
prognostic significance in breast cancer (Ellis et al.,
1985) although HMFG-1 and HMFG-2 were of
less value in similar studies (Wilkinson et al., 1984;
Berry et al., 1985). Antibodies like those of the Ca
series (Bramwell et al., 1985) have found
application as markers of malignant cells in
diagnostic cytological tests. On the other hand, the
11 5D8 antibody has been utilized for the
development of a sandwich immunoassay for the
determination of its target antigen (the so-called
MAM-6 antigen) in the circulation of breast cancer
patients, and MAM-6 antigen levels correlated with
tumour load (Hilkens et al., 1985). Thus, this
particular antibody has important diagnostic
applications.
The value of these antibodies reactive with
NCRC-11 antigen and related high molecular
weight mucins, for targeting agents to tumours
would be expected to be of limited value because of
the wide distribution of the relevant epitopes on
normal tissues. However, HMFG-1 and HMFG-2
antibodies have been employed for the radio-
diagnostic imaging of ovarian, breast and
gastrointestinal tumours (Epenetos et al., 1982) and
for the staging of cervical cancer by antibody
(HMFG-2) guided lymphangiography (Epenetos,
1985). In addition, therapeutic doses of 131I linked
to HMFG-2 antibodies have been administered to
patients with malignant effusions with encouraging
results (Epenetos, 1984).
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